Pharmafile Logo
T40 2022 Cover
Diversity, Equity and Inclusion
Communiqué 53 Cover Image
- PMLiVE

heart attack patients

National Institute for Health and Care Excellence NICE logo

NICE reverses negative guidance for Forxiga in diabetes

Final draft guidance backs the use of BMS/AstraZeneca’s SGLT-2 inhibitor in certain patients

- PMLiVE

AstraZeneca offers $443m to buy Omthera

Adds to list of deals to boost flagging pipeline

- PMLiVE

Roche repeats cancer drugs warning as Avastin faces another NICE rejection

Concerns about future of Cancer Drugs Fund

- PMLiVE

Novartis wins third NICE recommendation for Lucentis

Gains final backing to treat NHS patients with macular oedema

Former NICE chair joins board of biotech

Sir Michael Rawlins joins board of Intra-Cellular Therapeutics

National Institute for Health and Care Excellence NICE logo

NICE recommends Astellas’ Betmiga for overactive bladder

Final draft guidance recommends Vesicare successor

- PMLiVE

Value-based pricing “not in patient interest”

Think-tank 2020health calls for rethink of UK drug pricing plans

- PMLiVE

Redx Pharma to open research centre at AstraZeneca’s Alderley Park site

Will focus on hard-to-treat infections

- PMLiVE

NICE tasked with speeding NHS uptake of new technology

Expanded role will see it takeover the work of the NHS Technology Adoption Centre

- PMLiVE

Union calls on AstraZeneca to reconsider Alderley Park plans

Unite says move to Cambridge will take years to deliver value

Novartis building

NICE turns down Novartis’ blood cancer drug Jakavi

Uncertainties remain about drug’s cost-effectiveness, according to final draft guidance

- PMLiVE

AstraZeneca sales hit by Seroquel generics

End of patent exclusivity for antipsychotic among key factors dragging down revenues

Subscribe to our email news alerts

Latest jobs from #PharmaRole

Latest content

Latest intelligence

Quick links